Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
E William St ClairAlan N BaerChungwen WeiGhaith NoaisehAnne ParkeAndreea CocaTammy O UtsetMark C GenoveseDaniel J WallaceJames McNamaraKaren BoyleLynette Keyes-ElsteinJeffrey L BrowningNathalie FranchimontKira SmithJoel M GuthridgeIgnacio SanzJudith A Jamesnull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2018)
In this trial, treatment with baminercept failed to significantly improve glandular and extraglandular disease in patients with primary SS, despite evidence from mechanistic studies showing that it blocks LTβR signaling.